In contrast to other cancers where molecular classifications have guided targeted therapies (e.g., HER2 in breast cancer, EGFR in non-small cell lung cancer, or RAS/BRAF in colorectal cancer), there exists no molecular subclass of HCC that has an approved biomarker-driven therapy. Here, BRAF is linked to hepatocellular carcinoma.